Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Today, we talk about some highly anticipated data from Summit Therapeutics that could show how its bispecific antibody drug outperformed Keytruda in a head-to-head lung cancer trial. Also, positive data from Lilly on its weekly insulin, and we explore amylin as a target for obesity.
Biotechs bet on amylin as the next obesity target
The first GLP-1 diabetes drug, Byetta, was developed by a company called Amylin Pharmaceuticals. The company, as evidenced by its name, was also interested in using amylin, a peptide hormone secreted by the pancreas along with insulin, as a target for weight-loss drugs. It abandoned that approach because it needed to be injected too often.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
